Previously submitted to: JMIR Mental Health (no longer under consideration since Jan 20, 2026)
Date Submitted: Jan 20, 2026
Open Peer Review Period: Jan 20, 2026 - Jan 20, 2026
(closed for review but you can still tweet)
NOTE: This is an unreviewed Preprint
Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note "no longer under consideration" will appear above).
Peer review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a "Peer Review Me" button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.
Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
Final version: If our system detects a final peer-reviewed "version of record" (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.
Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.
Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Wearable-derived cardiovascular and autonomic changes associated with ADHD stimulant medication: A remote monitoring study of adults with ADHD
ABSTRACT
Background:
Adults with ADHD commonly receive treatment with stimulant medications. While clinical trials have documented cardiovascular associations of these medications, real-world continuous monitoring data capturing medication-related physiological patterns in naturalistic settings remain limited. Understanding such patterns through remote monitoring technologies could provide valuable insights for treatment optimization and safety monitoring.
Objective:
This study aimed to examine differences in autonomic and cardiovascular function between off-medication and on-medication phases in adults with ADHD using continuous wearable monitoring, while adjusting for lifestyle exposure (alcohol consumption, smoking) and time-of-day patterns.
Methods:
We conducted a within-individual observational cohort study with 12-month remote monitoring via wearable technology and mobile-health platform. The multi-center study was conducted at King's College London, United Kingdom, and Vall d'Hebron Research Institute, Spain. Participants were adults aged 18-60 with DSM-5 confirmed ADHD, recruited from adult ADHD clinic waiting lists before treatment initiation. Data were available from 199 participants who had reached the stable medication phase, of whom 104 met eligibility criteria with valid baseline (off-medication) and stable on-medication data (≥7 days of adequate wearable data per phase). The primary analysis examined changes in daytime (07:00-22:00) physiological measures between off-medication baseline and stable on-medication phases (28-day windows). The wearable device provided minute-level processed biomarkers including pulse rate, pulse rate variability, respiratory rate, electrodermal activity and skin temperature. Participant data were collected via the RADAR-base platform. Generalized linear mixed-effects models assessed medication associations, adjusting for age, site, alcohol use frequency and smoking status.
Results:
Analysis of 4,104 participant-days showed stimulant medication was associated with modest cardiovascular changes during daytime hours: mean daytime pulse increased 2.46 bpm (95% CI, 1.99-2.93; P<.001), respiratory rate 0.39 breaths/minute (95% CI, 0.21-0.56; P<.001), and maximum pulse rate variability 7.41 ms (95% CI, 3.15-11.65; P=.01). Electrodermal activity and skin temperature showed no consistent medication-related differences. Frequent alcohol consumption (≥4 times/week) was associated with higher pulse rate (+2.78 bpm; 95% CI, 0.80-4.77; P=.024), lower pulse rate variability (-11.88 ms; 95% CI, -19.86 to -3.90; P=.017), and elevated electrodermal activity (+0.90 µS; 95% CI, 0.25-1.56; P=.027). Current smoking was associated with higher pulse rate (+2.67 bpm; 95% CI, 0.73-4.60; P=.027) and respiratory rate (+1.66 breaths/minute; 95% CI, 0.83-2.49; P<.001).
Conclusions:
Real-world continuous monitoring demonstrates that stimulant medications for adult ADHD are associated with time-specific, modest cardiovascular changes. Frequent alcohol consumption and current smoking showed associations with cardiovascular parameters, highlighting the importance of comprehensive assessment in ADHD treatment. These findings support the value of digital health technologies and continuous physiological monitoring for understanding medication associations in naturalistic settings, with potential to inform personalized treatment approaches and safety monitoring protocols.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.